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ABSTRACT 
Introduction: multiple myeloma (MM) is a plasma cell disorder that represents the second most 
frequent hematologic cancer. Although MM is still an incurable disease, prognosis has improved in 
the last decade thanks to the introduction of novel agents such as proteasome inhibitors (PIs), 
immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors. 
Areas covered: ixazomib is the first oral PI recently approved by Food and Drug Administration (FDA) 
and European Medicine Agency (EMA) in combination with lenalidomide and dexamethasone as 
salvage therapy in MM patients. In this paper, we focus on its pharmacokinetics features, as well as 
its safety and efficacy in clinical studies.   
Expert opinion: ixazomib can be considered an oral analogue of bortezomib, with 9.5-day half-life, 
58% of oral bioavailability, and a large distribution volume of 543L. These features make it a versatile 
molecule, potentially useful both in combination and as single agent. Oral route of administration 
and good efficacy/safety profile are its winning characteristics, providing the rationale for a future 
role also in the maintenance setting. 
 
KEY WORDS: ixazomib, maintenance therapy, multiple myeloma, pharmacokinetics, proteasome 
inhibitors. 
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1. Introduction 
Multiple myeloma (MM) is a plasma cell dyscrasia that clinically manifests with hypercalcemia, renal 
insufficiency, anemia, and bone lesions [1]. It constitutes 13% of hematologic cancers and 2% of all 
cancers [2,3].  
Prognosis has improved in the last decade thank to introduction of novel agents such as proteasome 
inhibitors (PIs), immunomodulatory drugs (IMIDs), monoclonal antibodies (MoAbs), and histone 
deacetylase inhibitors.  
Generally, young fit patients are treated with novel agent-based induction followed by autologous 
stem cell transplantation (ASCT), whereas therapy of elderly, ASCT-ineligible patients consists of 
triplet or doublet combinations including novel agents. More recently, consolidation and long-term 
therapies (LTTs) are under evaluation to be implemented in standard treatment [4]. 
New drug development is crucial for the treatment of the disease that is characterized by clonal 
evolution and onset of chemotherapy resistance [5].  
Among PIs, ixazomib is the most recent to be approved by regulatory authorities in the relapse 
setting. In this paper, we focus on its pharmacokinetics features, as well as its safety and efficacy in 
clinical studies.   
 
2. Overview of the Market 
Bortezomib, approved by FDA in 2003 [6], was the first PI used in MM. At first, bortezomib was 
administered intravenously, subsequently, clinical trials showed improved safety with subcutaneous 
bortezomib,  leading to approval of subcutaneous injection use [7,8].  
In 2012, the second-generation, intravenous PI, carfilzomib received FDA approval for treatment of 
MM patients who have received ≥2 prior therapies including bortezomib and an IMID and have 
demonstrated disease progression on or within 60 days of completion of the last therapy. In 2015, 
carfilzomib was approved also in combination with lenalidomide and dexamethasone for the 
treatment of patients with relapsed/refractory MM (RRMM) who have received 1-3 prior lines of 
therapy [9].  
In this scenario, also the new PI ixazomib received approval by regulatory authorities (details of 
approval are reported in section 8).  
 
3. Introduction to the compound 
5 
 
Ixazomib citrate is the first orally available PI [10]. The standard dose is 4 mg on days 1, 8, 15 of 28-
day cycles. Although sharing some structural motifs and the same target with the previous approved 
PIs, bortezomib and carfilzomib, ixazomib citrate is the first PI prodrug with a distinct affinity and 
selectivity profile [11,12] [Table1]. 
 
3.1 Chemistry 
Ixazomib citrate, is a prodrug that, on exposure to plasma, is rapidly hydrolyzed to ixazomib, that is 
the active form (MLN2238, IUPAC name: [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-
methylbutyl]boronic acid) [13].  
Structurally, ixazomib is a dipeptidyl boronic acid-based compound consisting of an alanine-leucine 
dipeptide core with a citrate-protected boric acid [12].  
The molecular formula for ixazomib citrate is C20H23BCl2N2O9 and its molecular weight is 517.12 
g/mol.  The solubility of ixazomib citrate in 0.1N HCl (pH 1.2) at 37°C is 0.61 mg/mL. The solubility 
increases as the pH increases [14] (Box 1). 
 
3.2 Pharmacodynamics 
The ubiquitin-proteasome pathway, consisting of the ubiquitin-conjugating system and the 26S 
proteasome,  is involved in polyubiquitination and subsequent degradation of proteins. The 26S 
proteasome is made up of the 19S regulatory units and the 20S core particle, subdivided in two α- 
and β-rings, carrying catalytic activities referred to as chymotrypsin-like (CT-L), trypsin-like (T-L), and 
caspase-like(C-L), also called β5, β2, and β1 subunits, respectively [13,15]. 
Proteasome inhibition prevents degradation of IκB, which binds to NFκB in the cytoplasm, blocking 
nuclear entry of the transcription factor involved in cell-surviving, angiogenesis, bone remodeling, 
and cell invasiveness. Proteasomal activity suppression leads also to p27 accumulation, resulting in 
cell-cycle arrest and apoptosis. Another consequence of proteasome inhibition is up-regulation of 
pro-apoptotic factors - present at higher levels in myeloma cells due to increased amounts of 
misfolded immunoglobulin proteins - such as p53, Bax, and NOXA, together with reduction of anti-
apoptotic factors like Bcl-2 and IAP. Finally, PIs can prevent degradation of misfolded proteins, 
largely produced by myeloma cells, leading to their accumulation in the endoplasmic reticulum, 
causing cell death [16–20]. 
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Ixazomib is a selective, reversible and dose-dependent inhibitor of the 20S proteasome β5 subunit, 
with half maximal inhibitory concentration (IC50) value of 3.4 nmol/L  [13]. 
Although ixazomib selectivity and potency are similar to bortezomib, the proteasome dissociation 
half-life (t1/2) for ixazomib is approximately six times shorter than bortezomib, meaning a wider 
tissue distribution of the drug  [13] [Table1]. 
 
3.3 Pharmacokinetics and metabolism 
Ixazomib pharmacokinetics has been deeply explored in several studies. In this chapter we report 
the main features of ixazomib in terms of absorption, distribution, metabolism, and excretion.  
3.3.1 Absorption and distribution 
Ixazomib was initially dosed according to body-surface-area (BSA). Subsequently, a population 
pharmacokinetics model-based analysis of patients enrolled in four phase I studies showed that BSA 
did not influence ixazomib clearance or systemic exposure, allowing the switching from BSA-scaled 
to fixed dosing. 
Ixazomib is rapidly absorbed, with a median time to reach peak concentration (Tmax) of 
approximately 1 h postdose  [13,14,21] and a maximum observed plasma concentration (Cmax) of 
0,11 μg/ml at the clinical dosage of 4 mg weekly [22]. 
Area-under-concentration curve (AUC) increases proportionally over a dose range of 0.2 to 10.6 mg 
with a dose-linear model.  
A food effect study showed an AUC reduction by 28% after a high-fat meal [23]. For this reason, no 
food should be consumed for at least 2h before and 1h after drug administration. 
Analysis of data from 755 adult patients enrolled across ten studies established absolute oral 
bioavailability (F) to be 58% [24]. 
In vivo studies demonstrated that ixazomib is 99% bound to plasma proteins [21,22,24], explaining 
the rapid absorption and the long terminal half life [Table 2].  
The steady-state volume of distribution reported by different studies is 543L [22,24], providing 
further evidence of wide tissue distribution [13,18]. 
3.3.2 Metabolism 
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Ixazomib citrate is a prodrug that, in aqueous solutions or plasma, rapidly hydrolyzes to its 
biologically active form, ixazomib. In vitro studies using human cDNA-expressed cytochrome P450 
(CYP) isozymes showed that, at concentrations of 10 μM, seven major human CYP isozymes were 
involved: CYP3A4 (42.3%), 1A2 (26.1%), 2B6 (16.0%), 2C8 (6.0%), 2D6 (4.8%), 2C19 (4.8%), and 2C9 
(1%). Whereas at closer to clinically relevant concentration of 0.1 and 0.5 μM, non-CYP-mediated 
metabolism was observed, suggesting that, non-CYP proteins contribute to the clearance of 
ixazomib, and no specific CYP isozyme predominates [22,25]. 
Given the hepatic role in ixazomib metabolism, a study was conducted to characterize 
pharmacokinetics in patients with solid tumours and moderate or severe hepatic impairment [total 
bilirubin >1.5 X (upper limits of normal, ULN)]. In such patients, unbound and total systemic 
exposures of ixazomib were 27% and 20% higher, respectively, than in patients with normal hepatic 
function. Consequently, a reduced ixazomib starting dose of 3 mg is recommended for patients with 
moderate or severe hepatic impairment [26]. 
3.3.3 Excretion 
Ixazomib is a low clearance drug with a terminal half-life of 9.5 days, and a plasma clearance value 
of 1.86 L/h [24,25]. 
The mean renal clearance for oral ixazomib is estimated to be 0.119 L/h, which represents 6.4% of 
the total body clearance. Furthermore, considering the evidence that approximately 62% of the oral 
dose is excreted into urine, about 22% in the feces, and only 3.2% is eliminated unchanged in the 
urine up to 168 hours after oral dosing, metabolism is expected to be the major clearance 
mechanism for ixazomib [14,24,25]. 
Since MM is a disease associated with renal impairment at diagnosis in 15-40% of cases [27], a study 
was designed to investigate pharmacokinetics in patients with severe renal impairment (SRI) or end-
stage renal disease (ESRD) requiring haemodialysis. In SRI/ESRD patients unbound and total 
systemic exposures of ixazomib were 38% and 39% higher, respectively, compared to patients with 
normal renal function. Therefore, in case of SRI/ESRD a reduced starting dose of 3 mg is 
recommended [28]. 
 
4. Clinical efficacy 
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In phase I studies, ixazomib administered as single agent in heavily pre-treated patients, showed 
overall response rate (ORR) ranging between 15 and  18% [29,30]. Preclinical studies indicated a 
synergistic activity of ixazomib with lenalidomide. These results provided the basis for phase II trials 
in which ixazomib efficacy was explored both as single agent and in combination with lenalidomide 
and dexamethasone. 
In a phase II trial, ixazomib as single-agent was given to relapsed MM patients not bortezomib-
refractory, and the ORR was 34% [31]. 
Two doses of ixazomib (4 and 5.5 mg) given orally once-weekly (on days 1, 8 and 15 of a 28-day 
cycle) combined with dexamethasone were compared in RRMM patients. Both doses of ixazomib 
plus dexamethasone were safe and effective; ixazomib at the dose of 5.5 mg induced deeper 
responses (ORR: 38% vs 52%) but resulted in a higher rate of  grade ≥3 adverse events (21% vs 54%) 
[32]. 
Clinical efficacy of ixazomib-lenalidomide-dexamethasone combination in RRMM patients was 
confirmed in the phase III TOURMALINE-MM1 study, which, besides higher ORR in ixazomib vs 
placebo group (78% vs 72%, p 0.04), showed longer median PFS in favor of ixazomib (21 vs 15 
months, p 0.01). Moreover, by subgroup analysis, in high cytogenetics risk patients, PFS was 21 
months in ixazomib arm while PFS decreased to 10 months in placebo arm. Median overall survival 
(OS) was not reached in either group and follow-up is ongoing [33]. 
In newly diagnosed (ND)MM a phase I/II trial  enrolled 65 patients who were treated with ixazomib 
associated with lenalidomide and dexamethasone, leading to an ORR of 92% with complete 
response (CR) in 27% of patients. Estimated 2-year progression-free survival (PFS) was 66% [34]. 
A phase II study of ixazomib in combination with lenalidomide and dexamethasone was conducted 
also by the Intergroupe Francophone du Myélome (IFM) for NDMM patients. The combination was 
used both as induction prior to, and as consolidation following ASCT, showing an ORR of 81% after 
induction therapy. CR rate increased from 12% before ASCT, to 38% after transplantation, and to 
44% following consolidation [35]. 
Oral route of administration, weekly dosing schedule, and good safety/efficacy profile encouraged 
the evaluation of ixazomib in the maintenance setting. 
In the phase I/II trial mentioned above, 21 untreated MM patients not undergoing ASCT, who 
responded to induction therapy, started ixazomib maintenance:  33% deepened their responses, 
median time to best response was 7 months, and median duration of response was 26 months [36]. 
Ixazomib maintenance in combination with lenalidomide after ASCT was evaluated in 65 patients 
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enrolled in a phase II trial and the estimated 2-year PFS was 83% [37] [Table 3]. 
Currently, phase III trials TOURMALINE-MM3 and TOURMALINE-MM4 are ongoing to evaluate 
single-agent ixazomib as maintenance therapy in NDMM patients who received ASCT, and those 
who have not undergone ASCT, respectively [38]. 
 
5. Safety, tolerability, toxicity, and potential off-target effects related to safety liabilities  
A phase I, dose-escalation trial evaluated weekly ixazomib tolerability in 60 RRMM patients. One 
dose limiting toxicity (DLT) was grade (G) 3 nausea, vomiting and diarrhea, and occurred at the dose 
of 2.97 mg/m2. Two other DLTs were reported at the dose of 3.95 mg/m2 and were G3 nausea, 
vomiting and diarrhea, and G3 erythema multiforme rash. Maximum tolerated dose (MTD) was 
established at 2.97 mg/m2. Most relevant hematologic  G≥3 drug-related adverse events (AEs) were: 
thrombocytopenia (28%), neutropenia (13%), and lymphopenia (9%); while most frequent non-
hematologic drug-related G≥3 AEs were gastrointestinal, such as diarrhea (13%) and nausea (9%) 
[30]. 
Another phase I, dose-escalation study evaluated safety of the twice-weekly schedule in 60 RRMM 
patients. One patient experienced a DLT (G3 macular erythematous rash) at 2.23 mg/m2 dose. G4 
thrombocytopenia developed in another patient and it was considered as DLT, even though it did 
not formally meet all the definition criteria. MTD was determined to be 2.0 mg/m2. Most common 
drug-related G≥3 AEs were hematologic: thrombocytopenia (37%) and neutropenia (17%); among 
non-hematologic drug-related G≥3 AEs the most frequent were dermatologic (8%) [29]. 
Safety profile of ixazomib in combination with lenalidomide and dexamethasone was evaluated 
both in NDMM and RRMM patients. 
In a phase I/II trial, 65 NDMM patients were treated with ixazomib-lenalidomide-dexamethasone, 
followed by single-agent ixazomib as maintenance therapy. During phase I, four DLTs were 
experienced, one at 2.97 and three at 3.95 mg/m2, and the MTD was established at 2.23 mg/m2. 
G≥3 drug-related AEs were observed in 63% of patients, the most frequent were rash (17%), 
neutropenia (12%) and thrombocytopenia (8%). 
More consistent data on toxicity of ixazomib-lenalidomide-dexamethasone combination were 
provided in the TOURMALINE-MM1 study. This study compared the triple oral combination vs 
placebo-lenalidomide-dexamethasone in 722 RRMM patients. Among hematologic toxicities, G≥3 
thrombocytopenia was more frequent in  the ixazomib group (19% vs 9%), whereas the most 
relevant G≥3 non-hematologic AEs included rash (7% vs 4%) and diarrhea (6% vs 3%). The incidence 
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of peripheral neuropathy (PN) was 27% in the ixazomib group and 22% in the placebo group. Only 
2% of patients in each study arm had G3 events, and 4% in the ixazomib group and 3% in the placebo 
group had PN with pain. Discontinuation rate due to toxicity was 17% in ixazomib arm vs 14% in 
control one [33]. 
Maintenance therapy with single-agent ixazomib at weekly dosing schedule was evaluated in 21 
NDMM patients enrolled in a phase I/II trial. Seventy-one percent had drug-related AEs, 10% were 
G≥3 (thrombocytopenia and hypokalemia) [36]. 
Combination of ixazomib and lenalidomide as maintenance therapy showed a high toxicity:  the 
main hematologic G≥3 AEs were neutropenia (23%) and thrombocytopenia (11%), while the most 
frequent non-hematologic G≥3 AEs included infections (26%), rash (12%) and gastrointestinal 
toxicities [37] [Table 3]. 
 
6. Drug-drug interaction 
Drug-drug interaction may lead to suboptimal efficacy due to reduced drug exposure, or toxicity due 
to excessive compound plasma concentration. Most oral drugs are CYP450 substrates and lots of 
them are inducers or inhibitors of such enzymes. Ixazomib is a CYP3A4 substrate, therefore, 
concomitant administration of strong CYP3A4 inducers, such as rifampicin, phenytoin, 
carbamazepine, and St. John’s Wort (hypericum), is strictly prohibited. CYP1A2-modulatory drugs 
and smoking status were not found to influence ixazomib systemic clearance   [14,24,39]. 
 
7. Dosing routes  
Pharmacokinetic data from four phase 1 dose-escalation studies with MLN9708 showed that there 
was a rapid absorption of ixazomib after oral administration. Similar systemic exposures have been 
achieved during IV and oral administration of ixazomib [21].  For this reason, ixazomib has been 
administered orally since the first clinical phase I trials in MM. Intravenous administration was used 
only in two phase I studies in which ixazomib was evaluated in relapsed/refractory lymphoma and 
non-hematologic tumors  [25,40,41]. 
 
8. Regulatory affairs 
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Ixazomib (Ninlaro), marketed by Takeda Pharmaceuticals, on 27th  September 2011 was designated 
as “orphan medicine” for MM treatment. The FDA granted priority review because this application 
was considered of significant importance in terms of safety and efficacy for MM patients.  
In November 2015, the US FDA approved ixazomib in combination with lenalidomide and 
dexamethasone for the treatment of patients with MM who have received at least one prior therapy 
[14]. 
In September 2016, ixazomib in combination with lenalidomide and dexamethasone received a 
conditional approval also by European Medicine Agency (EMA) [42].  
 
9. Conclusion 
Ixazomib, the first oral PI marketed in 2015, is administered on empty stomach, on day 1, 8, 15 of 
28-day cycles at the dose of 4 mg. Starting dose reduction at 3 mg is required only in case of severe 
hepatic and renal impairment.  
Ixazomib could be defined as an oral analogue of bortezomib, being a boronic acid that reversibly 
inhibits β5 subunit of 20S proteasome. With a 9.5-day half-life, 58% of oral bioavailability, and a 
large distribution volume of 543 L, ixazomib is a versatile molecule, potentially useful both in 
combination with IMIDs, and as single-agent.  
TOURMALINE-MM1 trial showed its good efficacy/safety profile, with ORR of 78%, median PFS of 
21 months and a discontinuation rate due to AEs of 17% only, and led to FDA and EMA approval for 
use in combination with lenalidomide and dexamethasone as salvage treatment in RRMM.  
G≥3 AEs with ixazomib are low and easily manageable. In addition, this drug can be safely 
administered during dialysis, and confirmed to be effective in high-risk cytogenetic MM patients, 
thus paving the way  to its evaluation in other combinations and in the maintenance setting. 
 
10. Expert Opinion 
 
Ixazomib, compared to bortezomib and carfilzomib, has two particular advantages: the oral route 
of administration and a better toxicity profile. Indeed, its pharmacokinetic profile allows once-
weekly administration, improving quality of life and patient compliance while reducing hospital 
admissions for treatment. Moreover, data from TOURMALINE-MM1 showed easy-management of 
G≥3 AEs, mostly thrombocytopenia, neutropenia, nausea, diarrhea and skin rash. Bortezomib 
toxicity profile is characterized by development of poorly reversible PN of any grade in about 37% 
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of patients, including 14% of patients with G≥3 clinical manifestations [43]. By comparison, in 
TOURMALINE-MM1 PN of any grade was reported in 27% of patients and only in 4% it was 
associated with pain.  
The major concern with carfilzomib is the occurrence of cardiovascular toxicities, being 
hypertension and cardiac failure the most frequent G≥3 events, reported in 9% and 5% in the 
ENDEAVOR study, respectively, and in 4% in the ASPIRE trial [44,45]. In the TOURMALINE-MM1 
study, G≥3 hypertension and cardiac failure were reported in 3% and 2% of patients, without 
significant differences with the placebo arm. These data strongly suggest that ixazomib is not 
characterized by frequent cardiovascular toxicity.  
In terms of efficacy, in the TOURMALINE-MM1 study, ixazomib overcame the poor prognosis 
associated with high-risk cytogenetic abnormalities, especially del(17p) and t(4;14), thus improving 
PFS. Indeed, in high-risk patients treated with ixazomib-lenalidomide-dexamethasone, median PFS 
was 21.4 months while it was 9.7 months in the control arm (HR 0.543)[46]. In addition, ixazomib 
also improved PFS in, patients with amp(1q21), although the benefit was minor.  
The development of treatment-resistant clones is a possible cause of worsening in long-term 
outcomes, including PFS and OS, with increasing number of prior therapies. Although patients 
refractory to PIs or lenalidomide were excluded from TOURMALINE-MM1, the results of this trial 
demonstrated that PFS significantly improved by adding ixazomib to lenalidomide and 
dexamethasone in patients with 1 prior therapy without transplant (HR 0.60), and 2 or 3 previous 
lines of treatment (HR 0.58), regardless of previous exposure to PI or IMIDs. This benefit was 
reported also in patients refractory to their last therapy (HR 0.71)[47,48].  
Easy oral administration, good safety/efficacy profile, and the need for newer therapeutic strategies 
to face MM intrinsic chemoresistance and genetic instability, provide the rationale to implement 
and evaluate ixazomib in novel agent-combinations, such as with thalidomide, pomalidomide [49], 
panobinostat, selinexor, daratumumab, and also in association with conventional, more 
economically sustainable chemotherapeutic drugs, such as cyclophosphamide, and melphalan . [50–
56]   
Preliminary results (reported in Table 4) confirmed the good safety/efficacy profile of the 
aforementioned combinations.  
Maintenance therapy in the post-ASCT setting, and continuous therapy for ASCT-ineligible patients 
are defined LTTs and represent a new issue in MM therapeutic strategy. The goal of LTTs is to control 
minimal residual disease, thus prolonging PFS and OS. To be appropriate for LTTs, a drug should be 
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effective, safe, easy-to-take and, possibly, not excessively expensive. With the exception of cost 
issues, ixazomib seems to satisfy these requirements [57]. Furthermore, phase I and II trials showed 
promising results in the maintenance setting, both for ixazomib as single agent and in combination 
with lenalidomide. 
Based on the aforementioned considerations, two are the most probable fields in which ixazomib 
could be employed in the future: all-oral combinations both as front-line and salvage therapies, and 
LTTs.  
Data on long-range toxicity (including second primary malignancies) and chemoresistance 
stimulation are still needed and will be of crucial importance for the future role of this promising 
molecule. 
Head-to-head comparisons in well-designed clinical trials are needed to evaluate ixazomib and 
carfilzomib or bortezomib and to define the best choice in terms of safety/efficacy[58].  
Additionally, because modern anti-myeloma regimens typically combine a PI and an IMID and could 
cost at least 100.000 USD per year, also pharmaco-economic considerations need to be carefully 
addressed. Therefore, clinical trials are also needed to evaluate the most appropriate sequence of 
agents to be used, to determine which drug is the best option in specific subsets of  patients and 
disease settings, and to define the optimal duration of therapy, especially in the context of LTTs[58–
60]. 
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Table 1. Comparison between Bortezomib, Carfilzomib and Ixazomib [3] 
 Bortezomib Carfilzomib Ixazomib 
Chemical structure 
 
 
 
 
 
 
 
Mechanism of 
proteasome 
inhibition 
Slowly-reversible inhibition 
of the β5 CT-L and β1 C-L 
subunit  
Irreversible inhibition  of the β5 CT-L 
subunit  
Reversible inhibition of the β5 
CT-L subunit  
Proteasome 
dissociation half-life 
(t1/2) 
Slowly reversible: 110 
minutes 
Irreversible Reversible: 18 minutes 
Administration Intravenous/Subcutaneous Intravenous Oral 
Treatment 
indication 
NDMM or RRMM RRMM RRMM 
CT-L, chymotrypsin-like; C-L, caspase-like; NDMM, newly diagnosed multiple myeloma; RRMM, 
relapsed/refractory multiple myeloma; 
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Table 2. Pharmacokinetics characteristics of ixazomib at 4 mg weekly 
Parameter Value 
Cmax (μg/ml) 
Tmax (h) 
t1/2 (days) 
0,11 
1.0 
9.5 
F (%) 
PPB (%) 
58 
99 
CL (L/h) 1.86 
Cmax, maximum observed plasma concentration; Tmax, first time of Cmax; t1/2, half-life; F, oral bioavailability; 
PPB, plasma protein binding; CL, plasma clearance; 
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Box 1. Drug Summary 
Drug name Ixazomib Citrate (Ninlaro, Takeda) 
Indication Multiple Myeloma 
Phase Approved by FDA in combination with lenalidomide 
and dexamethasone in relapsed/refractory patients 
that have received at least one prior therapy 
Pharmacology Inhibitor of 5 subunit of 20S proteasome 
Description Proteasome inhibitor 
Route of administration Oral 
Chemical structure 
 
2,2'-{2-[(1R)-1-{[N-(2,5-
Dichlorobenzoyl)glycyl]amino}-3-methylbutyl]-5-
oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid 
Pivotal trial(s) NCT01564537 
 
17 
 
Table 3: summary of most relevant clinical trials evaluating safety and efficacy of ixazomib both as single agent and in combination with lenalidomide and 
dexamethasone. 
Authors of the 
study 
Phase 
N° of 
patients 
Type 
of MM 
Median 
number 
of prior 
therapies 
Study design 
Safety Efficacy 
DLTs/MTD 
Main 
hematologic G≥3 
AEs 
Main non-
hematologic 
G≥3 AEs 
ORR 
Median 
PFS 
Kumar et al. 
[30] 
I 60 RRMM 6 
Ixazomib at 
0.24, 0.48, 0.8, 
1.2, 1.68, 2.23, 
2.97, 3.95 
mg/m2 orally on 
days 1, 8, and 
15 of a 28-day 
cycle for 12 
cycles 
G3 nausea, 
vomiting and 
diarrhea at 2.97 
and 3.95 mg/m2 
G3 rash at 3.95 
mg/m2 
MTD at 2.97 
mg/m2 
thrombocytopeni
a (28%) 
neutropenia 
(13%) 
diarrhea (13%) 
nausea (9%) 
18% n.e. 
Richardson et 
al. [29] 
I 60 RRMM 4 
Ixazomib at 
0.24, 0.48, 0.8, 
1.2, 1.68, 2.0, 
2.23 mg/m2 
orally on days 1, 
4, 8, 11 of a 21-
day cycle for 12 
cycles 
G3 rash at 2.23 
mg/m2 
G4 
thrombocytope
nia at 2.23 
mg/m2 
MTD at 2.0 
mg/m2 
thrombocytopeni
a (37%) 
neutropenia 
(17%) 
skin and 
subcutaneous 
tissue 
disorders (8%) 
15% n.e. 
Kumar et al. 
[31] 
II 33 RRMM 2 
Ixazomib orally 
at a dose of 
5.5 mg on days 
1, 8 and 15 of a 
28-day cycle. 
Dexamethasone 
at a dose of 
20 mg orally 
was added on 
days 1, 2, 8, 9, 
15 and 16 of 
the 28-day 
n.e. thrombocytopeni
a (45%) 
 
diarrhea (20%) 34% 11 
months
* 
18 
 
cycle for lack of 
minor response 
by end of cycle 
2, lack of a PR 
by end of cycle 
4, or disease 
progression at 
any time 
Moreau et al. 
[33] 
III 
722 
randomized 
in 1:1 ratio 
RRMM 
Range 1-
3 
Oral ixazomib 
or placebo at a 
dose of 4 mg on 
days 1, 8, and 
15;  
plus 
lenalidomide 25 
mg orally on 
days 1-21 and 
dexamethasone 
40 mg orally on 
days 1, 8, 15, 
and 22 of 28-
day cycles until 
disease 
progression or 
development of 
unacceptable 
toxicities 
n.e. thrombocytopeni
a  
(19% vs 9%) 
 
rash (7% vs 
4%)  
diarrhea (6% 
vs 3%) 
78% vs 
72%, p 
0.04 
21 vs 
15 
months
, p 0.01 
Kumar et al. 
[34] 
I/II 
65 
(15 in 
phase I and 
50 in phase 
II) 
NDMM 0 
Phase I: oral 
ixazomib at  
1.68, 2.23, 2.97, 
and 3.95 mg/m2 
Phase II: oral 
ixazomib at 4 
mg on days 1, 8, 
15  
1 DLT at 2.97 
mg/m2 
3 DLTs at 3.95 
mg/m2 
MTD at 2.23 
mg/m2 
converted to 
fixed dose of 4 
neutropenia 
(12%) 
thrombocytopeni
a (8%) 
skin and 
subcutaneous 
tissue 
disorders 
(17%) 
92% 67% 
(estima
ted 2-
year) 
19 
 
plus  
lenalidomide 25 
mg orally on 
days 1–21 and 
dexamethasone 
40 mg orally on 
days 1, 8, 15, 22 
of a 28-day 
cycle for  12 
cycles, followed 
by maintenance 
therapy with 
ixazomib alone 
mg on the basis 
of 
pharmacokineti
cs results 
Kumar et al. 
[36] 
I/II 21 NDMM 0 
Maintenance 
with ixazomib 4 
mg orally on 
days 1, 8, 15 of 
28-day cycles 
n.e. thrombocytopeni
a (5%) 
hypokalemia 
(5%) 
2 VGPR to 
n-CR,  
3 VGPR to 
CR, 1 
VGPR to 
sCR, 
1 CR to 
sCR 
n.e. 
Shah et al. [37] II 65 NDMM 0 
Maintenance 
with ixazomib 4 
mg orally on 
days 1, 8, 15, 
and 
lenalidomide 10 
mg orally 
(increased to 15 
mg after 3 
months if well 
tolerated) on 
days 1-28 of 28-
day cycles 
n.e. neutropenia 
(23%) 
thrombocytopeni
a (11%) 
infections 
(26%) 
rash (12%) 
n.e. 83% 
(estima
ted 2-
year)  
20 
 
Legend: N°: number; MM: multiple myeloma; DLT: dose limiting toxicity; MTD: maximum tolerated dose; G: grade; AEs: adverse events; ORR: overall response 
rate; PFS: progression-free survival; RRMM: relapsed/refractory multiple myeloma; NDMM: newly diagnosed multiple myeloma; n.e.: not evaluated; *: event-
free survival (EFS); VGPR: very good partial response; nCR: near complete response; CR: complete response; sCR: stringent complete response. 
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Table 4: summary of most relevant clinical trials evaluating safety and efficacy of ixazomib in novel, all oral combinations. 
Authors of 
the study 
Phase 
n of 
patients 
Type of 
MM 
Median 
number of 
prior 
therapies 
Study design Safety Efficacy 
San Miguel 
et al[55]  
I 38 NDMM n.a. 
Arm A: Ixa 3.0-3.7 mg (days 1, 4, 8, 
11, 22, 25, 29, 32) plus M 9 mg/m2 
and P 60 mg/m2 (days 1-4) in 42-
day cycles (max 9 cycles);  
Arm B: Ixa 3.0-4.0 mg (days 1, 8, 
15) plus M 6 mg/m2 and P 60 
mg/m2 (days 1-4) in 28-day cycles 
(max 13 cycles);  
Arm C/D: Ixa 3.0-4.0 mg (days 1, 8, 
15, 22, 29)/Ixa 4.0 mg (days 1, 8, 
22, 29) plus M 9 mg/m2 and P 60 
mg/m2 (days 1-4) in 42-day cycles 
(max 9 cycles) 
10 DLTs:  G3 rash (n=2, Arm A), G≥3 
thrombocytopenia (n=4, 1 pt in each Arm), 
G≥3 neutropenia (n=1, Arm A; n=4, Arm C; 
n=1, Arm D), G4 hemorrhagic esophageal 
ulcer (n=1, Arm B), G3 ileus/neurogenic 
bladder (n=1, Arm B), G3 vomiting/diarrhea 
(n=1, Arm B), and G3 respiratory infection 
(n=1, Arm C) 
n.e. 
San Miguel 
et al[55] 
II 61 NDMM n.a. 
Ixa 4.0 mg (days 1, 8, 15) plus M 6 
mg/m2 and P 60 mg/m2 (days 1-4) 
in 28-day cycles (max 13 cycles) 
followed by Ixa maintenance (days 
1, 8, 15; 28-day cycles) 
G≥3 thrombocytopenia: 49%, G≥3 
neutropenia: 44%, G≥3 infections: 13%, G≥3 
diarrhea: 11%, G≥3 rash: 7% 
ORR 66% 
(CR 26%), 
median 
PFS 23.5 
m 
Dimopoulos 
et al[56] 
II 70 NDMM n.a. 
Ixa 4.0 mg plus Cy 300 mg/m2 (Arm 
A) or 400 mg/m2 (Arm B) on days 
1, 8, and 15, and D 40 mg on days 
1, 8, 15, and 22, for up to 13 28-
day cycles followed by Ixa 
maintenance therapy 
G≥3 neutropenia: 31%, G≥3 anemia: 14%, G≥3 
respiratory infections: 13%, G≥3  
supraventricular  arrhythmias: 7% 
ORR 76% 
(CR 13%), 
median 
PFS n.r. 
Voorhees et 
al[52] 
I 17 RRMM ≥2 
Pom 2-4 mg on days 1-21 plus Ixa 
3-4 mg on days 1, 8 and 15 and D 
40 mg (20 mg if age >75 years) on 
days 1, 8, 15 and 22 of 28-day 
2 DLTs: 1 febrile neutropenia at Pom 4 mg and 
Ixa 3 mg, 1 G4 thrombocytopenia at Pom 4 mg 
and Ixa 4 mg 
ORR 62% 
22 
 
cycles until disease progression or 
unacceptable toxicity 
G≥3 neutropenia: 35%, G≥3 lymphopenia: 
29%, G≥3 thrombocytopenia: 18% 
Krishnan et 
al[61] 
I/II 21 RRMM 3 
Ixa 3-4 mg on days 1, 8 and 15 plus 
Pom 4 mg on days 1-21 and D 40 
mg of 28-day cycles until disease 
progression or unacceptable 
toxicity 
1 DLT: G3 lung infection at Ixa 3 mg 
MTD: Ixa 4 mg 
ORR 40% 
Reu et al[50] I 11 RRMM 5 
Ixa 3-4 mg on days 1, 8, 15 plus 
Pan 20 mg (days 1, 3, 5, 15, 17, 19) 
and D 20 mg (days 1, 2, 8, 9, 15, 
16) of 28-day cycles 
No DLTs 
G≥3 neutropenia: 18%, G≥3 
thrombocytopenia: 9% 
n.a. 
Ludwig et 
al[49] 
II 77 RRMM 1 
Ixa 4 mg on days 1, 8 and 15 plus T 
100 mg/day, and D 40 mg on days  
1, 8, 15. If age ≥75 years T 50 
mg/day and D 20 mg. Max 8 cycles 
followed by Ixa maintenance for 1 
year (Ixa 4 mg or 3 mg if age ≥75 
years on days 1, 8, 15; 28-day 
cycles)  
G≥3 anemia: 13%, G≥3 thrombocytopenia: 
9%, G≥3 neutropenia: 6%, all grades 
pneumonia: 9% 
0RR 63%, 
median 
PFS 11.6 
m 
Legend: n: number; MM: multiple myeloma; NDMM: newly diagnosed multiple myeloma; n.a.: not available; Ixa: ixazomib; M: melphalan; P: prednisone;  DLT: 
dose limiting toxicity; G: grade; n.e.: not evaluated; ORR: overall response rate; CR: complete response; PFS: progression-free survival; m: months; Cy: 
cyclophosphamide; D: dexamethasone; n.r.: not reached; RRMM: relapsed/refractory multiple myeloma; T: thalidomide; Pom: pomalidomide; MTD: maximum 
tolerated dose; Pan: panobinostat 
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Annotations: 
Ref 24. **Important study of ixazomib pharmacokinetics. 
Ref 26. *Pharmacokinetic analysis of ixazomib in hepatic impairment and consequences for clinical 
safety. 
Ref 28. *Pharmacokinetic analysis of ixazomib in renal failure and consequences for clinical safety. 
